Tennessee Strikes a New Chord in Healthcare: What House Bill 2246 Means for Stem Cell Therapy

Known as a powerhouse of music history, Tennessee is setting the tone for a different kind of breakthrough: stem cell therapy. The Volunteer State is stepping into a new era of regenerative medicine with House Bill 2246, a landmark effort to create a clear, patient-focused framework for how these therapies can be safely offered.

Sponsored by Representative Chris Hurt, the bill reflects a growing reality in modern healthcare: innovation is moving faster than regulation. Rather than waiting years for federal approval processes to catch up, Tennessee is working to bridge that gap — giving patients access to emerging treatments while putting thoughtful guardrails in place.

At its core, House Bill 2246 allows physicians to offer certain stem cell and regenerative therapies that have not yet been approved by the U.S. Food and Drug Administration (FDA), as long as those treatments fall within their scope of practice — particularly in areas like orthopedics, wound care, and pain management.

But this isn’t a “wild west” approach to medicine. The legislation is carefully structured to prioritize safety, transparency, and accountability.

A Framework Built Around Patient Protection

One of the most important aspects of the bill is its emphasis on where stem cells come from and how they are handled. Under the new law, all stem cells used in treatment must be sourced from facilities that are registered with the FDA or accredited by recognized organizations in the field.

That means patients are gaining access to therapies that meet strict quality and manufacturing standards.

Physicians are also required to:

• Obtain written informed consent from patients before treatment
• Clearly disclose when a therapy is not FDA-approved in any advertising
• Encourage patients to consult their primary care provider before proceeding
• Report adverse events and complications, helping create a feedback loop that can improve safety and inform future care.

These measures aim to ensure that patients fully understand both the potential and the limitations of stem cell therapies before making a decision.

What This Means Moving Forward

If fully enacted, the law could take effect later in 2026, with rulemaking beginning soon after approval. Tennessee would join a small but growing number of states shaping their own approach to regenerative medicine — potentially influencing how other states think about innovation in healthcare.

For many patients, especially those dealing with chronic pain or slow-healing injuries, regenerative medicine represents hope. Supporters of the bill argue that it opens the door to treatments that may improve quality of life without forcing patients to wait for lengthy federal timelines.

“Stem cell therapy is a lifeline for many,” Rep. Hurt said when the bill passed, emphasizing the importance of balancing innovation with public health protections.